OTC Markets OTCPK - Delayed Quote USD

BrainsWay Ltd. (BRSYF)

3.4000

0.0000

(0.00%)

At close: April 17 at 4:00:00 PM EDT

Steris Stock Gets Relative Strength Rating Lift

A Relative Strength Rating upgrade for Steris shows improving technical performance. Will it continue?

Investor's Business Daily last month

MASI

BRSYF
0.00%
BWAY
-1.32%
BrainsWay Ltd (BRSYF) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

BrainsWay Ltd (BRSYF) reports a 27% revenue increase and outlines plans for continued growth and innovation in 2025.

GuruFocus.com last month

BWAY
-1.32%
BrainsWay Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

Achieved record quarterly sales of $11.4 million in Q4 2024, an increase of 27% compared with Q4 2023 Full year 2024 revenue increased nearly 30% YoY to $41 million Exceeded full year 2024 operating income and Adjusted EBITDA margin guidance Company expects continued strong growth in 2025, with revenue of $49 million to $51 million and further improvement in profit and profitability Conference call to be held today at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, March 11, 2025 (GLOBE NEWSWIRE) --

GlobeNewswire last month

BRSYF
0.00%
BWAY
-1.32%
BrainsWay to Present at the Oppenheimer 35th Annual Healthcare MedTech & Services Conference

BURLINGTON, Mass. and JERUSALEM, March 04, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that management will present virtually at the Oppenheimer 35th Annual Healthcare MedTech & Services Conference at 9:20 AM EST on March 18, 2025. A live webcast of the presentation will be available on the Events & News – Presentations page of the Com

GlobeNewswire last month

BRSYF
0.00%
BWAY
-1.32%
BWAY Drops 15% in Four Days: How to Play the Stock Before Earnings?

BWAY stock continues to struggle near its IPO price despite growth. With rising revenues, global expansion and valuation concerns, is it a buy, hold or sell before earnings?

Zacks last month

BWAY
-1.32%
BrainsWay to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025

BURLINGTON, Mass. and JERUSALEM, Israel, Feb. 24, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its fourth quarter and full year 2024 financial results, as well as operational highlights, before the open of the U.S. financial markets on Tuesday, March 11, 2025. The Company will host a conference call and webcast at 8:

GlobeNewswire last month

BRSYF
0.00%
BWAY
-1.32%
Brainsway Ltd. Sponsored ADR (BWAY) Hit a 52 Week High, Can the Run Continue?

Brainsway (BWAY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks last month

BWAY
-1.32%
PAHC
Outbrain (OB) and Brainsway (BWAY) Are Aggressive Growth Stocks

Two More Stocks for your Aggressive Growth Stock Radar Screen.

Zacks 2 months ago

OB

BWAY
-1.32%
Brainsway Ltd. Sponsored ADR (BWAY) Soars to 52-Week High, Time to Cash Out?

Brainsway (BWAY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks 2 months ago

BWAY
-1.32%
RMD
Brainsway (BWAY) Moves 8.0% Higher: Will This Strength Last?

Brainsway (BWAY) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Zacks 2 months ago

BWAY
-1.32%
ATRC
Earnings Estimates Rising for Brainsway (BWAY): Will It Gain?

Brainsway (BWAY) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Zacks 3 months ago

BWAY
-1.32%
Wall Street Analysts Think Brainsway (BWAY) Could Surge 38.83%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 38.8% in Brainsway (BWAY). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks 3 months ago

BWAY
-1.32%
New Strong Buy Stocks for January 14th

BWAY, EE, MATW, BRBR and FMAO have been added to the Zacks Rank #1 (Strong Buy) List on January 14, 2025.

Zacks 3 months ago

BWAY
-1.32%
SBH

TV
Are Medical Stocks Lagging Brainsway (BWAY) This Year?

Here is how Brainsway Ltd. Sponsored ADR (BWAY) and Butterfly Network, Inc. (BFLY) have performed compared to their sector so far this year.

Zacks 3 months ago

BWAY
-1.32%
BFLY-WS
Brainsway reports independent pilot data on Deep TMS technology for AUD

BrainsWay (BWAY) announced recent positive pilot data from an independent, third-party study conducted at Stanford University evaluating an accelerated protocol using the Company’s Deep Transcranial Magnetic Stimulation, TMS, technology to treat alcohol use disorder, AUD, patients. The outcomes were reported in a publication in the Brain Stimulation journal entitled, “Accelerated deep TMS in alcohol use disorder: A preliminary pilot trial targeting the dorsal anterior cingulate cortex increases

TipRanks 4 months ago

BRSYF
0.00%
BWAY
-1.32%
BrainsWay Reports Positive Independent Pilot Data on Accelerated Deep TMS Treatment of Alcohol Use Disorder

BURLINGTON, Mass. and JERUSALEM, Dec. 12, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced non-invasive treatment of brain disorders, today announced recent positive pilot data from an independent, third-party study conducted at Stanford University evaluating an accelerated protocol using the Company’s Deep Transcranial Magnetic Stimulation (TMS) technology to treat alcohol use disorder (AUD) patients. The outcomes were

GlobeNewswire 4 months ago

BRSYF
0.00%
BWAY
-1.32%
BrainsWay Reports Promising Feasibility Data Showing Pain Reduction with Deep TMS Therapy

Reductions also seen in comorbid anxiety and depression symptomsBURLINGTON, Mass. and JERUSALEM, Israel, Nov. 20, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the publication of positive feasibility clinical data evaluating the analgesic effects of deep transcranial magnetic stimulation (Deep TMS™) in patients with peripheral neuropathi

GlobeNewswire 4 months ago

BRSYF
0.00%
BWAY
-1.32%
BrainsWay Reports Third Quarter 2024 Financial Results and Operational Highlights

Robust 26% Year-over-Year Revenue Growth in Q3 2024 Raising Full-Year 2024 Revenue Guidance to $40-41 Million and Initiating Profitability Guidance Conference Call to be Held Today at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, Israel, Nov. 12, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today reported third quarter 2024 financial results and provided

GlobeNewswire 5 months ago

BRSYF
0.00%
BWAY
-1.32%
Is Brainsway (BWAY) Stock Outpacing Its Medical Peers This Year?

Here is how Brainsway Ltd. Sponsored ADR (BWAY) and Intuitive Surgical, Inc. (ISRG) have performed compared to their sector so far this year.

Zacks 5 months ago

BWAY
-1.32%
ISRG
BrainsWay to Report Third Quarter 2024 Financial Results On November 12, 2024

BURLINGTON, Mass. and JERUSALEM, Oct. 29, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its third quarter 2024 financial results as well as operational highlights before the open of the U.S. financial markets on Tuesday, November 12, 2024. The Company will host a conference call and webcast at 8:30 AM Eastern Time to

GlobeNewswire 5 months ago

BRSYF
0.00%
BWAY
-1.32%

Performance Overview

Return	BRSYF	TA-125 (^TA125.TA)
YTD	-60.14%	+4.48%
1-Year	+37.65%	+32.35%
3-Year	-15.00%	--

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

BrainsWay Ltd. (BRSYF)

Steris Stock Gets Relative Strength Rating Lift

BrainsWay Ltd (BRSYF) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

BrainsWay Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

BrainsWay to Present at the Oppenheimer 35th Annual Healthcare MedTech & Services Conference

BWAY Drops 15% in Four Days: How to Play the Stock Before Earnings?

BrainsWay to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025

Brainsway Ltd. Sponsored ADR (BWAY) Hit a 52 Week High, Can the Run Continue?

Outbrain (OB) and Brainsway (BWAY) Are Aggressive Growth Stocks

Brainsway Ltd. Sponsored ADR (BWAY) Soars to 52-Week High, Time to Cash Out?

Brainsway (BWAY) Moves 8.0% Higher: Will This Strength Last?

Earnings Estimates Rising for Brainsway (BWAY): Will It Gain?

Wall Street Analysts Think Brainsway (BWAY) Could Surge 38.83%: Read This Before Placing a Bet

New Strong Buy Stocks for January 14th

Are Medical Stocks Lagging Brainsway (BWAY) This Year?

Brainsway reports independent pilot data on Deep TMS technology for AUD

BrainsWay Reports Positive Independent Pilot Data on Accelerated Deep TMS Treatment of Alcohol Use Disorder

BrainsWay Reports Promising Feasibility Data Showing Pain Reduction with Deep TMS Therapy

BrainsWay Reports Third Quarter 2024 Financial Results and Operational Highlights

Is Brainsway (BWAY) Stock Outpacing Its Medical Peers This Year?

BrainsWay to Report Third Quarter 2024 Financial Results On November 12, 2024

Performance Overview